News

A new feature on NeurologyLive®, IJMSC Insights offers a closer look at the latest research and the people behind it from the community of the International Journal of Multiple Sclerosis Care (IJMSC) and the Consortium of Multiple Sclerosis Centers (CMSC).

In a recent analysis, acute levodopa induced a robust short-duration response (SDR) and long-duration response (LDR), with further improvement in the combined SDR plus LDR state in patients with Parkinson disease.

The positive data report could potentially build on phase 2 study of Duchenne muscular dystrophy in which CAP-1002 met its primary end point.

The system vice chair for the department of neurology at Allegheny Health Network discussed the shift in migraine treatment over the past few years with the approval of new therapies and allowing patients more options for their health. [WATCH TIME: 4 minutes]

New preliminary data showed that more than 50% of dosed pediatric patients with X-linked myotubular myopathy achieved ventilator independence, with some attaining the ability to walk independently.

In a recently published study, findings revealed that mitochondrial dysfunction in patients with idiopathic REM sleep behavior disorder may serve as a predictor for the progression of Parkinson disease.

The senior vice president, global head of medical affairs, and chief medical officer at Acadia Pharmaceutical, provided an overview of LILAC-2, a long-term, open-label study assessing the treatment benefits of trofinetide (Daybue). [WATCH TIME: 6 minutes]

Lobule VIIB showed a non-linear pattern of lower volume with each Hoehn and Yahr-increment bilaterally, with the most significant group differences at stages 4-5 compared with controls.

In recent conversations with experts in epilepsy, the impact of stigmatization remains high for patients and ongoing efforts by clinicians to address this issue in the clinical setting has been underscored, despite the global lack of awareness about new treatments and other resources.

Also known as ATH-1017, fosgonimeton demonstrated a safe profile, with directional improvements in cognitive, functional, and biomarker assessments.

The OneRF Ablation System follows the Evo cortical and sEEG electrode product lines, marking a significant step in NeuroOne's journey to offer innovative solutions for neurological conditions.

The chief medical officer at Biohaven provided clinical insight on the mechanism of action of BHV-7000, an antiseizure medication, and its supportive phase 1 data. [WATCH TIME: 4 minutes]

The frequent use of REN wearable device for the acute treatment of migraine was shown to reduce the number of monthly treatments in adolescents, with a similar reduction in migraine and headache days seen in a pivotal prevention trial in adults.

Maura McCarthy, head of corporate development at Skyhawk Therapeutics, provided comment on a new phase 1 study assessing SKY-0515, a small molecule candidate as a potential treatment for Huntington disease.

The research project manager at the TSC Alliance provided additional clarity into a new study presented at AES 2023 assessing the links between TSC-associated neuropsychiatric disorders and seizure duration. [WATCH TIME: 4 minutes]

Episode 40 of the AUPN Leadership Minute features Clifton L. Gooch, MD, of the University of South Florida; and Tom Frontera, MD, of the University of South Florida. [WATCH TIME: 9 minutes]

Pitolisant demonstrated a dose-dependent improvement in excessive daytime sleepiness and fatigue, with a safety profile that was consistent with previous studies. Additional data to be shared in early 2024.

A new feature on NeurologyLive®, IJMSC Insights offers a closer look at the latest research and the people behind it from the community of the International Journal of Multiple Sclerosis Care (IJMSC) and the Consortium of Multiple Sclerosis Centers (CMSC).

Here's some of what is coming soon to NeurologyLive® this week.

The health economics outcomes research specialist at UCB talked about a retrospective analysis assessing the persistence of fenfluramine (Fintepla) in Dravet syndrome over 12 months, compared with valproate and levetiracetam. [WATCH TIME: 4 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is ataxia.

Neurology News Network for the week ending December 9, 2023. [WATCH TIME: 3 minutes]

While specialists still debate the diagnostics of impaired cognition, the identification of patients at the earliest stages is beginning to be met through new biomarkers and available assays.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 8, 2023.

The assistant professor of neurology at the University of Virginia talked about findings from a comprehensive study on epilepsy and mild cognitive impairment, which was recently presented at AES 2023. [WATCH TIME: 5 minutes]

Catch up on any of the neurology news headlines you may have missed over the course of November 2023, compiled all into one place by the NeurologyLive® team.

The research scientist at NYU Langone Health talked about findings from preclinical data investigating epileptiform activity in mouse models of Alzheimer disease, which were presented at AES 2023. [WATCH TIME: 4 minutes]

Using outcomes such as the CDR-SB, ADAS-Cog12, MMSE, and ADCOMS, patients treated with NE3017 for 6 months demonstrated equal, if not greater, improvements than traditional antiamyloid therapies at 18 months.